Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | S100A4 | P26447 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxorubicin SCHEMBL317301 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL9335136 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL6251124 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL3242 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL571906 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL317302 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL6423994 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21669731 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21669733 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL5324652 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702481-B2 | Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof | BLUEFIN BIOMEDICINE, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-115087638-A | PRMT5 inhibitor | 默沙东公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-2971010-B1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-8694555-B2 | Processing drug data | DRUGLOGIC, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20120209864-A1 | PROCESSING DRUG DATA | QED SOLUTIONS, INC. | 2012-08-16 | — | — | US | disclosed |
| CN-102471351-A | 2-carboxamide cyclosemicarbazides as PI3K inhibitors | NOVARTIS AG | 2012-05-23 | — | — | CN | disclosed |
| US-8131769-B2 | Processing drug data | DRUGLOGIC, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| CN-102065886-A | Modified hyaluronidases and their use in the treatment of hyaluronic acid related diseases and disorders | HALOZYME INC | 2011-05-18 | — | — | CN | disclosed |
| US-7846431-B2 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases | HALOZYME, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100125615-A1 | PROCESSING DRUG DATA | QED SOLUTIONS, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| CN-101360740-A | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMA (US) | 2009-02-04 | — | — | CN | disclosed |
| CN-101132783-A | Apogossypolone and the uses thereof | UNIV MICHIGAN (US) | 2008-02-27 | — | — | CN | disclosed |
| US-20020188465-A1 | Processing drug data | DRUGLOGIC, INC. | 2002-12-12 | — | — | US | disclosed |
| US-5922350-A | DEHYDRATION IN PRESENCE OF SUGARS PRESENT AT A PROTECTIVECONCENTRATION ON BOTH INSIDE AND OUTSIDE SURFACES; LIPOSOMESHAVE ION CONCENTRATION GRADIENT CAPABLE OF GENERATINGTRANSMEMBER POTENTIAL TO LOAD CHARGED MATERIAL | THE LIPOSOME COMPANY, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| US-5837279-A | DEHYDRATION IN PRESENCE OF PROTECTIVE SUGARS, STORAGE, REHYDRATION; LOADING CHARGED MATERIALS | THE LIPSOME COMPANY, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5736155-A | LOADING IONIZABLE ANTITUMOR AGENTS USING TRANSMEMBRANE POTENTIALS REDUCING RATE OF DRUG RELEASE | THE LIPOSOME COMPANY, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| US-5672688-A | STABILITY | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-09-30 | — | — | US | disclosed |
| US-5652274-A | PYRUVATES, FATTY ACIDS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC | 1997-07-29 | — | — | US | disclosed |
| US-5578320-A | PREPARING A COMPOSITION OF UNILAMELLAR LIPOSOMES WITH A PROTECTIVE SUGAR AND REMOVING WATER | THE LIPOSOME COMPANY, INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-4880635-A | PROTECTIVE SUGARS, MEMBRANES | THE LIPOSOME COMPANY, INC. (US) | 1989-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702481-B2 | Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof | CD2BP2, CDCA2, CSPP1 | TOP2A 2308/4885MEN1 1477/4885KMT2A 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.